Oriol Mirallas

Prof. Dr. Oriol Mirallas

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
David James PinatoDavid James Pinato
David James Pinato
AZAlberto Zambelli
Alberto Zambelli
JAJuan Aguilar-Company
Juan Aguilar-Company
PBProfessor Mark Bower
Professor Mark Bower
CSChristopher C.T. Sng
Christopher C.T. Sng
JSJudith Swallow
Judith Swallow
The SARS-CoV-2 pandemic significantly affected oncology practice across the globe. There is uncertainty as to the contribution of patients9 demographics and oncologic features to severity and mortality from COVID-19 and little guidance as to the role of anticancer and anti–COVID-19 therapy in this population. In a multicenter study of 890 patients with cancer with confirmed COVID-19, we demonstrated a worsening gradient of mortality from breast cancer to hematologic malignancies and showed that male gender, older age, and number of comorbidities identify a subset of patients with significantly worse mortality rates from COVID-19. Provision of chemotherapy, targeted therapy, or immunotherapy did not worsen mortality. Exposure to antimalarials was associated with improved mortality rates independent of baseline prognostic factors. This study highlights the clinical utility of demographic factors for individualized risk stratification of patients and supports further research into emerging anti–COVID-19 therapeutics in SARS-CoV-2–infected patients with cancer. Significance: In this observational study of 890 patients with cancer diagnosed with SARS-CoV-2, mortality was 33.6% and predicted by male gender, age ≥65, and comorbidity burden. Delivery of cancer therapy was not detrimental to severity or mortality from COVID-19. These patients should be the focus of shielding efforts during the SARS-CoV-2 pandemic. This article is highlighted in the In This Issue feature, p. 1426

16 September 2011 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
RNRekek Negga
Rekek Negga
JSJ. Andrew Stuart
J. Andrew Stuart
MMMorgan L. Machen
Morgan L. Machen
JSJoel Salva
Joel Salva
ALAmanda J. Lizek
Amanda J. Lizek
VFVanessa A. Fitsanakis
Vanessa A. Fitsanakis

7 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
FMFrancesca Mateo
Francesca Mateo
ZHZhengcheng He
Zhengcheng He
LMLin Mei
Lin Mei
GGGorka Ruiz de Garibay
Gorka Ruiz de Garibay
CHCarmen Herranz
Carmen Herranz
MPMiquel Angel Pujana
Miquel Angel Pujana
Breast cancer risk for carriers of BRCA1 pathological variants is modified by genetic factors. Genetic variation in HMMR may contribute to this effect. However, the impact of risk modifiers on cancer biology remains undetermined and the biological basis of increased risk is poorly understood. Here, we depict an interplay of molecular, cellular, and tissue microenvironment alterations that increase BRCA1-associated breast cancer risk. Analysis of genome-wide association results suggests that diverse biological processes, including links to BRCA1-HMMR profiles, influence risk. HMMR overexpression in mouse mammary epithelium increases Brca1-mutant tumorigenesis by modulating the cancer cell phenotype and tumor microenvironment. Elevated HMMR activates AURKA and reduces ARPC2 localization in the mitotic cell cortex, which is correlated with micronucleation and activation of cGAS-STING and non-canonical NF-κB signaling. The initial tumorigenic events are genomic instability, epithelial-to-mesenchymal transition, and tissue infiltration of tumor-associated macrophages. The findings reveal a biological foundation for increased risk of BRCA1-associated breast cancer.

16 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
IBIosune Baraibar
Iosune Baraibar
OMOriol Mirallas
Oriol Mirallas
NGNadia Saoudi Gonzalez
Nadia Saoudi Gonzalez
JRJavier Ros
Javier Ros
FBFrancesc Salvà Salva Ballabrera
Francesc Salvà Salva Ballabrera
EEElena Elez
Elena Elez
In recent years, deepening knowledge of the complex interactions between the immune system and cancer cells has led to the advent of effective immunotherapies that have revolutionized the therapeutic paradigm of several cancer types. However, colorectal cancer (CRC) is one of the tumor types in which immunotherapy has proven less effective. While there is solid clinical evidence for the therapeutic role of immune checkpoint inhibitors in mismatch repair-deficient (dMMR) and in highly microsatellite instable (MSI-H) metastatic CRC (mCRC), blockade of CTLA-4 or PD-L1/PD-1 as monotherapy has not conferred any major clinical benefit to patients with MMR-proficient (pMMR) or microsatellite stable (MSS) mCRC, reflecting 95% of the CRC population. There thus remains a high unmet medical need for the development of novel immunotherapy approaches for the vast majority of patients with pMMR or MSS/MSI-low (MSI-L) mCRC. Defining the molecular mechanisms for immunogenicity in mCRC and mediating immune resistance in MSS mCRC is needed to develop predictive biomarkers and effective therapeutic combination strategies. Here we review available clinical data from combinatorial therapeutic approaches using immunotherapy-based strategies for MSS mCRC.

1 June 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
David James PinatoDavid James Pinato
David James Pinato
LSLorenza Scotti
Lorenza Scotti
AGAlessandra Gennari
Alessandra Gennari
ECEmeline Colomba-Blameble
Emeline Colomba-Blameble
SDSaoirse Dolly
Saoirse Dolly
ACAlessio Cortellini
Alessio Cortellini

10 June 2022 in ESMO Open
Verified
Journal Article
Open access
OMOriol Mirallas
Oriol Mirallas
DLD. López-Valbuena
D. López-Valbuena
DGD. García-Illescas
D. García-Illescas
CFC. Fabregat-Franco
C. Fabregat-Franco
HVH. Verdaguer
H. Verdaguer
TMT. Macarulla
T. Macarulla
Biliary tract cancers (BTCs) are a rare and heterogenous group with an increasing incidence and high mortality rate. The estimated new cases and deaths of BTC worldwide are increasing, but the incidence and mortality rates in South East Asia are the highest worldwide, representing a real public health problem in these regions. BTC has a poor prognosis with a median overall survival <12 months. Thus, an urgent unmet clinical need for BTC patients exists and must be addressed. The backbone treatment of these malignancies is chemotherapy in first- and second-line setting, but in the last decade a rich molecular landscape has been discovered, expanding conceivable treatment options. Some druggable molecular aberrations can be treated with new targeted therapies and have already demonstrated efficacy in patients with BTC, improving clinical outcomes, such as the FGFR2 or IDH1 inhibitors. Many other molecular alterations are being discovered and the treatment of BTC will change in the near future from our current clinical practice. In this review we discuss the epidemiology, molecular characteristics, present treatment approaches, review the recent therapeutic advances, and explore future directions for patients with BTC. Due to the rich molecular landscape of BTC, molecular profiling should be carried out early. Ongoing research will bring new targeted treatments and immunotherapy in the near future.